Browsing by Author "Ozsahin, M."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Outcome and prognosticators in adult patients with medulloblastoma: a Rare Cancer Network study
    (ELSEVIER IRELAND LTD, 2016-01-01) Atalar, B.; Ozsahin, M.; Call, J.; Napieralska, A.; Kamer, S.; Salvador, V.; Erpolat, P.; Negretti, L.; Ramstad, Y. L.; Onal, C.; Akyurek, S.; Ugurluer, G.; Baumert, B.; Servagi-Vernat, S.; Miller, R. C.; Ozyar, E.; Sio, T.
  • Thumbnail Image
    Item
    Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
    (OXFORD UNIV PRESS, 2011-01-01) Onal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.
    Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74\% and 71\%, respectively, and the disease-free survival (DFS) rates were 68\% and 64\%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.